How much profit has Crossject made this year?
Crossject has made 15.97 M EUR this year.
Crossject Net Income 2025
Crossject Net Income
15.97 M EUR
Ticker
ALCJ.PA
ISIN
FR0011716265
WKN
A1XEH4
In 2025, Crossject's profit amounted to 15.97 M EUR, a -243.5% increase from the -11.13 M EUR profit recorded in the previous year.
The Crossject Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2026e | 26.33 |
| 2025e | 15.97 |
| 2024e | -11.13 |
| 2023 | -8.64 |
| 2022 | -11.16 |
| 2021 | -10.81 |
| 2020 | -9.84 |
| 2019 | -7.17 |
| 2018 | -10.71 |
| 2017 | -7.61 |
| 2016 | -6.66 |
| 2015 | -5.69 |
| 2014 | -4.34 |
| 2013 | -1.82 |
| 2012 | -0.93 |
| 2011 | 1.55 |
| 2010 | -4.12 |
Crossject Revenue, EBIT, Net Income FR0011716265 · A1XEH4
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Crossject, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Crossject from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Crossject’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Crossject. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Crossject’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Crossject’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Crossject’s growth potential.
Crossject Revenue, EBIT and net profit per share
| Date | Crossject Revenue | Crossject EBIT | Crossject Net Income |
|---|---|---|---|
| 2026e | 54.29 M undefined | 33.66 M undefined | 26.33 M undefined |
| 2025e | 36.15 M undefined | 17.38 M undefined | 15.97 M undefined |
| 2024e | 8.42 M undefined | -11.68 M undefined | -11.13 M undefined |
| 2023 | 145,000 undefined | -11.8 M undefined | -8.64 M undefined |
| 2022 | 954,000 undefined | -13.29 M undefined | -11.16 M undefined |
| 2021 | 912,000 undefined | -11.82 M undefined | -10.81 M undefined |
| 2020 | 0 undefined | -10.67 M undefined | -9.84 M undefined |
| 2019 | 500,000 undefined | -8.64 M undefined | -7.17 M undefined |
| 2018 | 0 undefined | -11.56 M undefined | -10.71 M undefined |
| 2017 | 0 undefined | -8.62 M undefined | -7.61 M undefined |
| 2016 | 0 undefined | -7.29 M undefined | -6.66 M undefined |
| 2015 | 0 undefined | -7.01 M undefined | -5.69 M undefined |
| 2014 | 0 undefined | -5.11 M undefined | -4.34 M undefined |
| 2013 | 0 undefined | -2.62 M undefined | -1.82 M undefined |
| 2012 | 350,000 undefined | -1.42 M undefined | -930,000 undefined |
| 2011 | 650,000 undefined | -1.85 M undefined | 1.55 M undefined |
| 2010 | 200,000 undefined | -4.43 M undefined | -4.12 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2010 | 200,000 EUR | -4.43 M EUR | -4.12 M EUR |
| 2011 | 650,000 EUR | -1.85 M EUR | 1.55 M EUR |
| 2012 | 350,000 EUR | -1.42 M EUR | -930,000 EUR |
| 2013 | 0 EUR | -2.62 M EUR | -1.82 M EUR |
| 2014 | 0 EUR | -5.11 M EUR | -4.34 M EUR |
| 2015 | 0 EUR | -7.01 M EUR | -5.69 M EUR |
| 2016 | 0 EUR | -7.29 M EUR | -6.66 M EUR |
| 2017 | 0 EUR | -8.62 M EUR | -7.61 M EUR |
| 2018 | 0 EUR | -11.56 M EUR | -10.71 M EUR |
| 2019 | 500,000 EUR | -8.64 M EUR | -7.17 M EUR |
| 2020 | 0 EUR | -10.67 M EUR | -9.84 M EUR |
| 2021 | 912,000 EUR | -11.82 M EUR | -10.81 M EUR |
| 2022 | 954,000 EUR | -13.29 M EUR | -11.16 M EUR |
| 2023 | 145,000 EUR | -11.8 M EUR | -8.64 M EUR |
| 2024e | 8.42 M EUR | -11.68 M EUR | -11.13 M EUR |
| 2025e | 36.15 M EUR | 17.38 M EUR | 15.97 M EUR |
| 2026e | 54.29 M EUR | 33.66 M EUR | 26.33 M EUR |
Crossject stock margins FR0011716265 · A1XEH4
The Crossject margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Crossject. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Crossject.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Crossject's sales revenue. A higher gross margin percentage indicates that the Crossject retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Crossject's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Crossject's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Crossject's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Crossject. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Crossject's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Crossject Margin History
| Crossject Gross margin | Crossject Profit margin | Crossject EBIT margin | Crossject Profit margin |
|---|---|---|---|
| 2026e | 1,885.52 % | 62.01 % | 48.49 % |
| 2025e | 1,885.52 % | 48.08 % | 44.18 % |
| 2024e | 1,885.52 % | -138.76 % | -132.25 % |
| 2023 | 1,885.52 % | -8,137.93 % | -5,957.24 % |
| 2022 | 724.21 % | -1,392.87 % | -1,169.5 % |
| 2021 | 604.28 % | -1,296.38 % | -1,184.87 % |
| 2020 | 1,885.52 % | 0 % | 0 % |
| 2019 | -389.28 % | -1,728.6 % | -1,434.74 % |
| 2018 | 1,885.52 % | 0 % | 0 % |
| 2017 | 1,885.52 % | 0 % | 0 % |
| 2016 | 1,885.52 % | 0 % | 0 % |
| 2015 | 1,885.52 % | 0 % | 0 % |
| 2014 | 1,885.52 % | 0 % | 0 % |
| 2013 | 1,885.52 % | 0 % | 0 % |
| 2012 | -145.71 % | -405.71 % | -265.71 % |
| 2011 | -81.54 % | -284.62 % | 238.46 % |
| 2010 | -925 % | -2,215 % | -2,060 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2010 | -925 % | -2,215 % | -2,060 % |
| 2011 | -81.54 % | -284.62 % | 238.46 % |
| 2012 | -145.71 % | -405.71 % | -265.71 % |
| 2013 | 1,885.52 % | 0 % | 0 % |
| 2014 | 1,885.52 % | 0 % | 0 % |
| 2015 | 1,885.52 % | 0 % | 0 % |
| 2016 | 1,885.52 % | 0 % | 0 % |
| 2017 | 1,885.52 % | 0 % | 0 % |
| 2018 | 1,885.52 % | 0 % | 0 % |
| 2019 | -389.28 % | -1,728.6 % | -1,434.74 % |
| 2020 | 1,885.52 % | 0 % | 0 % |
| 2021 | 604.28 % | -1,296.38 % | -1,184.87 % |
| 2022 | 724.21 % | -1,392.87 % | -1,169.5 % |
| 2023 | 1,885.52 % | -8,137.93 % | -5,957.24 % |
| 2024e | 1,885.52 % | -138.76 % | -132.25 % |
| 2025e | 1,885.52 % | 48.08 % | 44.18 % |
| 2026e | 1,885.52 % | 62.01 % | 48.49 % |
Crossject Aktienanalyse
What does Crossject do?
Crossject SA is a company that specializes in the development and manufacturing of innovative drug delivery systems. The company was founded in 2006 by a team of professionals with the goal of changing the way medications are administered. Crossject's history began with the development of a unique drug delivery system called ZENEO. This system is based on a proprietary technology called "Needle Free Injection" that allows for needle-free and painless medication administration. The technology is safe, easy to use, and enables the administration of liquid medications and even solids in the form of suspensions. Crossject specializes in the application of this technology and develops products in various areas, including adrenaline for the treatment of life-threatening allergic reactions, methotrexate for the treatment of cancer, and anti-inflammatory medications for the treatment of asthma and COPD. The business model of Crossject is based on the development and commercialization of products based on the ZENEO technology. The company collaborates with a range of partners to bring its products to market, including pharmaceutical companies and other drug manufacturers. Crossject aims to sell its products worldwide and already has distribution partners in various countries around the world. Crossject is also committed to advancing the development of new products based on this technology. The company invests a significant portion of its revenue in research and development and works closely with academic institutions and other research facilities to improve its technology and products. Crossject's product offering includes a wide range of medications used for the treatment of various conditions. One example is the adrenaline injection system developed for the rapid and effective treatment of anaphylactic shocks that can occur as severe allergic reactions in people with food allergies, insect venom allergies, or drug allergies. The system does not require a needle and is therefore easy and safe to handle. Another example is the methotrexate injection for the treatment of cancer and autoimmune diseases such as rheumatoid arthritis and psoriasis. Crossject has also developed a range of products to combat asthma and chronic obstructive pulmonary disease (COPD). In 2019, the company received regulatory approval for its first commercial ZENEO product as an emergency treatment for migraines. This product is a fast-acting migraine therapy that is administered subcutaneously to quickly and effectively relieve pain and accompanying symptoms of migraines. In summary, Crossject is an innovative company specializing in the development and commercialization of drug delivery systems. The company utilizes a proprietary technology that allows for needle-free and painless medication administration and collaborates closely with partners to sell its products worldwide. Crossject continues to invest in research and development to bring new products based on its technology to market and establish itself as a leading company in its field. Crossject ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Crossject's Profit Margins
The profit margins of Crossject represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Crossject's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Crossject's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Crossject's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Crossject’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Crossject stock
How has the profit developed compared to last year?
The profit has increased by -243.5% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Crossject publish its earnings?
Crossject publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Crossject?
The profits of Crossject are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Crossject?
You can learn more about the earnings of Crossject by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Crossject pay?
Over the past 12 months, Crossject paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Crossject is expected to pay a dividend of 0 EUR.
What is the dividend yield of Crossject?
The current dividend yield of Crossject is .
When does Crossject pay dividends?
Crossject pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Crossject?
Crossject paid dividends every year for the past 0 years.
What is the dividend of Crossject?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Crossject located?
Crossject is assigned to the 'Health' sector.
Wann musste ich die Aktien von Crossject kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Crossject from 3/10/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 3/10/2025.
When did Crossject pay the last dividend?
The last dividend was paid out on 3/10/2025.
What was the dividend of Crossject in the year 2024?
In the year 2024, Crossject distributed 0 EUR as dividends.
In which currency does Crossject pay out the dividend?
The dividends of Crossject are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Crossject
Our stock analysis for Crossject Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Crossject Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
